Approximately 10–20% of breast cancers are triple‐negative breast cancer (TNBC), a subtype characterized by immunohistochemical lack of estrogen receptor (ER), progesterone receptor (PgR), and human epidermal growth factor receptor 2 (HER2) overexpression [1, 2, 3]. This evidence concerns the gene PGR and breast cancer.